Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Allergy. 2016 Sep 30;72(3):483–491. doi: 10.1111/all.13048

Table 2.

Within-subjects improvement in patient reported outcome measures following endoscopic sinus surgery.

Baseline Mean ± SD Last Follow-up Mean ± SD Within- subject Δ Mean ± SD 95% CI for Δ [LB, UB] p-value
All subjects:
miniAQLQ total score (n=61) 4.6 ± 1.3 5.0 ± 1.5 0.5 ± 1.1 [0.2, 0.7] 0.002
 Symptom score 4.2 ± 1.4 4.9 ± 1.6 0.7 ± 1.2 [0.3, 1.0] <0.001
 Activity score 5.3 ± 1.4 5.6 ± 1.6 0.3 ± 1.4 [0.02, 0.7] 0.056
 Emotional function score 4.7 ± 1.6 5.2 ± 1.7 0.4 ± 1.2 [0.1, 0.8] 0.004
 Environmental stimuli score 4.1 ± 1.6 4.4 ± 1.6 0.3 ± 1.6 [−0.1, 0.7] 0.186
ACT total score (n=52) 18.5 ± 4.9 19.8 ± 5.0 1.3 ± 4.1 [0.2, 2.4] 0.025
Subjects with preoperative uncontrolled asthma: (n=28)
miniAQLQ total score 3.9 ± 1.0 4.7 ± 1.6 0.7 ± 1.3 [0.3, 1.2] 0.004
 Symptom score 3.6 ± 1.1 4.5 ± 1.7 0.9 ± 1.3 [0.4, 1.4] 0.001
 Activity score 4.7 ± 1.3 5.4 ± 1.7 0.7 ± 1.6 [0.1, 1.3] 0.023
 Emotional function score 4.1 ± 1.5 4.7 ± 1.9 0.6 ± 1.3 [0.1, 1.1] 0.026
 Environmental stimuli score 3.4 ± 1.5 4.1 ± 1.6 0.7 ± 1.7 [0.04, 1.3] 0.036
ACT total score 15.0 ± 3.9 17.9 ± 5.8 2.9 ± 4.4 [1.2, 4.6] 0.002
All subjects CRS-specific quality of life scores: (n=61)
SNOT-22 total score 60.1 ± 19.6 26.3 ± 19.8 −33.8 ± 22.8 [−39.5, −28.1] <0.001
 Rhinologic symptoms 18.5 ± 6.4 8.3 ± 6.0 −10.2 ± 7.5 [−12.0, −8.3] <0.001
 Extra-nasal rhinologic symptoms 9.7 ± 2.9 4.9 ± 3.5 −4.8 ± 3.8 [−5.8, −3.9] <0.001
 Ear / facial symptoms 10.0 ± 5.6 4.2 ± 4.5 −5.8 ± 5.4 [−7.1, −4.4] <0.001
 Psychological dysfunction 18.2 ± 7.5 7.3 ± 7.6 −10.9 ± 8.9 [−13.1, −8.7] <0.001
 Sleep dysfunction 15.8 ± 6.0 7.3 ± 6.7 −8.5 ± 7.0 [−10.3, −6.8] <0.001

SD, standard deviation; Δ, delta (change); LB, lower bound; UB, upper bound; CI, confidence interval; SNOT-22, 22-item SinoNasal Outcome Test; miniAQLQ, the Mini Asthma Quality of Life Questionnaire; ACT, the Asthma Control Test; Within-subject improvement in all outcome measures was evaluated using either matched pairs t-testing or Wilcoxon signed-rank testing, depending on distribution normality.